Pharma

Your Article Summary

See Latest Articles

FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Corporate News Releases - The Healthcare Sales & Marketing Network, 12/02/08

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development